Growth hormone is used to treat twice as many short boys than girls in the U...( Boys are twice as likely as girls in...),Health
Boys are twice as likely as girls in the U.S. and Asia (mostly Japan) to receive recombinant human growth hormone (rhGH) for growth hormone deficiency, illnesses that affect height, and short stature of a non-medical nature. A smaller gender difference exists in Europe, Australia and New Zealand, but in the rest of the world short boys and girls are treated at the same rate. This indicates a likely cultural bias for male height in some countries.
The study, by researchers from The Childrens Hospital of Philadelphia and Pfizer, is electronically available prior to publication in the Journal of Clinical Endocrinology and Metabolism.
All children entered in the Pfizer International Growth Study (KIGS), a database designed to document long-term outcomes and safety of Genotropin, one of the three leading commercial brands of rhGH, were categorized by gender, location, date and age of therapy initiation, and diagnosis. Measures of national health status, health care expenditures, general economic indices and mean adult heights were also compared. Children were categorized into four geographic regions including the U.S., Europe/Australia/New Zealand, Asia and the Rest of the World.
Recombinant human growth hormone has been available since 1985. Because reports found more U.S. males receiving rhGH in its first years of availability, and rhGH use has increased considerably over the past 20 years, we thought it was important to get an up-dated look at the gender-based patterns of use in the U.S. and how they compared to other countries, said Adda Grimberg, M.D., lead author of the study and a pediatric endocrinologist at The Childrens Hospital of Philadelphia. We suspect that social and cultural pressures, combined with financial constraints, contribute to the international differences in the gender distributions of children treated with rhGH.
Historical trends revealed a consistent overall male predominance among U.S. pediatric rhGH
'/>"/>
| Contact: Joey Marie McCool McCool@email.chop.edu 267-426-6070 Children's Hospital of Philadelphia Source:Eurekalert |
Related medicine news :
1. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
2. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
3. Greenway Medical Technologies Experiences Continued Growth in OB/GYN Marketplace
4. BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond
5. Exercise may lead to faster prostate tumor growth
6. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
7. The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of Affordable Luxury Mini Day Spa Concept
8. Too many gene copies stimulate tumor cell growth
9. Data-handling technique finds genes to be team players in curbing brain cancer cell growth
10. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
11. CompareNetworks, Inc. Fuels Growth by Raising Round of Financing
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |